December 14, 2021 10:32 AM EST

Novartis enlists Molecular Partners on radioligand therapy discovery; Galera blames CRO error for PhIII failure — claims success after all

Paul Schloesser

Associate Editor

Amber Tong

A setback in Covid-19 didn’t stop Novartis from teaming up with Molecular Partners again. And this time, they will be looking for radiopharmaceuticals.

Having bet …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis enlists Molecular Partners on radioligand therapy discovery; Galera blames CRO error for PhIII failure — claims success after all

Paul Schloesser

Associate Editor

Amber Tong

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

No­var­tis en­lists Mol­e­c­u­lar Part­ners on ra­di­oli­gand ther­a­py dis­cov­ery; Galera blames CRO er­ror for PhI­II fail­ure — claims suc­cess af­ter all

Associate Editor

Sign up to read this article for free.

Novartis enlists Molecular Partners on radioligand therapy discovery; Galera blames CRO error for PhIII failure — claims success after all